A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

Overview of attention for article published in Neuro-Oncology, April 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

So far, Altmetric has seen 1 blog post.

El Servei d'Oncologia Mèdica de l'Hospital Universitari Son Espases ha participat en la publicació d'un assaig en fase II…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.